Methyldopa Aspen (Anhydrous Methyldopa)

• Methyldopa is employed in the management of hypertension and related conditions by targeting central sympathetic pathways.
• Essential hypertension: provides sustained blood pressure reduction in adult patients with primary hypertension.
• Pregnancy‑induced hypertension: helps control elevated blood pressure safely during gestation, reducing maternal risk.
• Renal‑associated hypertension: lowers systemic pressure in patients with chronic kidney disease, supporting renal protection.
• Secondary hypertension due to endocrine disorders: assists in managing blood pressure when caused by hormonal imbalances.
• Hypertensive emergencies (adjunct): may be used as part of combination therapy for rapid blood pressure control under specialist supervision.

• Methyldopa is a central alpha‑2 adrenergic agonist. After oral absorption, it is converted to alpha‑methyldopa, which stimulates presynaptic α2 receptors in the brainstem. This activation inhibits norepinephrine release, decreasing sympathetic outflow to peripheral vessels and the heart. The resulting reduction in peripheral vascular resistance and cardiac output leads to a gradual lowering of arterial blood pressure. The effect is dose‑dependent and persists with continued therapy.

Methyldopa may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness: feeling of sleepiness or reduced alertness.
• Dry mouth: decreased salivation causing throat discomfort.
• Headache: mild to moderate head pain.
• Orthostatic hypotension: dizziness upon standing due to blood pressure drop.
• Nasal congestion: blocked nasal passages.
• Fatigue: persistent lack of energy.

Serious or Rare Side Effects

• Liver dysfunction: elevated enzymes or hepatitis.
• Hemolytic anemia: destruction of red blood cells leading to fatigue.
• Lupus‑like syndrome: joint pain, rash, and fever resembling systemic lupus.
• Severe depression: persistent low mood and suicidal thoughts.
• Agranulocytosis: dangerously low white blood cell count.

When prescribing methyldopa, clinicians should observe several precautionary measures to ensure safe use.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Gradual discontinuation: taper dose to prevent rebound hypertension.
• Liver function assessment: evaluate hepatic enzymes before and during therapy.
• Depression screening: monitor patients for mood changes or suicidal thoughts.
• Renal dose adjustment: modify dosage in patients with impaired kidney function.
• Pregnancy counseling: discuss potential risks and benefits with pregnant patients.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Methyldopa can affect the activity of several medicines, requiring careful management of co‑administered drugs.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use can precipitate severe hypertension or hypertensive crisis due to opposing mechanisms.
• Direct vasodilators (e.g., nitroprusside): combined effect may cause excessive drop in blood pressure.
• Sympathomimetic agents (e.g., epinephrine, phenylephrine): may counteract methyldopa’s antihypertensive action and reduce efficacy.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood pressure reduction may require dose adjustment of one or both agents.
• Calcium channel blockers: potential for enhanced hypotensive response, especially with dihydropyridine types.
• NSAIDs: may blunt methyldopa’s blood pressure‑lowering effect by promoting sodium retention.
• Diuretics: concurrent therapy can increase risk of orthostatic hypotension and electrolyte imbalance.